{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AFQ056",
    "query": {
      "intervention": "AFQ056"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 18,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AFQ056&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T14:54:05.344Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01433354",
      "title": "Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 119,
      "start_date": "2011-11",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-03-24",
      "last_synced_at": "2026-09-02T14:54:05.344Z",
      "location_count": 7,
      "location_summary": "Sacramento, California • Decatur, Georgia • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01433354"
    },
    {
      "nct_id": "NCT02920892",
      "title": "AFQ056 for Language Learning in Children With FXS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Language Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Elizabeth Berry-Kravis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "32 Months",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "32 Months to 6 Years"
      },
      "enrollment_count": 110,
      "start_date": "2017-08-17",
      "completion_date": "2022-05-17",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-09-02T14:54:05.344Z",
      "location_count": 14,
      "location_summary": "Davis, California • Denver, Colorado • New Haven, Connecticut + 11 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02920892"
    },
    {
      "nct_id": "NCT06136195",
      "title": "Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol Consumption",
        "Heavy Drinker",
        "Alcohol Use Disorder (AUD)"
      ],
      "interventions": [
        {
          "name": "Mavoglurant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 63,
      "start_date": "2024-07-01",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-02T14:54:05.344Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06136195"
    },
    {
      "nct_id": "NCT05203965",
      "title": "Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Familial Alcoholism Vulnerability"
      ],
      "interventions": [
        {
          "name": "Mavoglurant (AFQ056)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 80,
      "start_date": "2022-05-17",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-09",
      "last_synced_at": "2026-09-02T14:54:05.344Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05203965"
    },
    {
      "nct_id": "NCT01482143",
      "title": "Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "3 Years to 11 Years"
      },
      "enrollment_count": 21,
      "start_date": "2012-03",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-09-02T14:54:05.344Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Chicago, Illinois • Nashville, Tennessee",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482143"
    },
    {
      "nct_id": "NCT01491529",
      "title": "Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyskinesias",
        "Parkinson Disease",
        "Movement Disorders",
        "Parkinsonian Disorders",
        "Anti-Dyskinesia Agents"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 154,
      "start_date": "2012-04",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-09-02T14:54:05.344Z",
      "location_count": 5,
      "location_summary": "Sunnyvale, California • Englewood, Colorado • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01491529"
    },
    {
      "nct_id": "NCT01813019",
      "title": "Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Patient Diagnosed With OCD and Resistant to SSRI Treatment",
        "Failed SSRI Over 12 Weeks at Appropriate Doses"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2013-11",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2017-01-02",
      "last_synced_at": "2026-09-02T14:54:05.344Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Watertown, Massachusetts • Brooklyn, New York",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Watertown",
          "state": "Massachusetts"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01813019"
    },
    {
      "nct_id": "NCT03327792",
      "title": "Mavoglurant in Alcohol Drinking",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol Drinking"
      ],
      "interventions": [
        {
          "name": "Mavoglurant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 34,
      "start_date": "2018-02-07",
      "completion_date": "2023-07-13",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-09-02T14:54:05.344Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03327792"
    },
    {
      "nct_id": "NCT01092065",
      "title": "Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "AFQ056 with L-dopa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 23,
      "start_date": "2010-03",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-09-02T14:54:05.344Z",
      "location_count": 4,
      "location_summary": "Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana + 1 more",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01092065"
    },
    {
      "nct_id": "NCT01173731",
      "title": "Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Dyskinesia, Drug-Induced",
        "Levodopa"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 66,
      "start_date": "2010-10",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-09-02T14:54:05.344Z",
      "location_count": 3,
      "location_summary": "Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01173731"
    }
  ]
}